All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ADC Developments in HER2– Breast Cancer Treatment Shake Up Paradigm

March 3rd 2023

As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.

FDA Expands Abemaciclib Indication in HR+/HER2–, Node+, High-Risk Breast Cancer

March 3rd 2023

The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.

Pilewskie Highlights Trends for Surgical Management of High-risk Breast Lesions

March 3rd 2023

Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®

Fox Chase Researchers Receive $1 Million Grant to Develop Platform That Could Assist in Development of New Drugs

March 3rd 2023

John Karanicolas, PhD, co-leader of the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, was recently awarded a $1 million grant from the W.M. Keck Foundation to develop a platform that could assist in the development of new drugs.

Miami Breast Cancer Conference Celebrates 40 Years

March 3rd 2023

The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.

Temferon Lands FDA Orphan Drug Status for Glioblastoma Multiforme

March 2nd 2023

The FDA has granted an orphan drug designation to Temferon for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Approval Sought for Cosibelimab in Metastatic or Locally Advanced CSCC

March 2nd 2023

A biologics license application seeking the approval of cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma has been accepted for filing by the FDA.

Enfortumab Vedotin Plus Pembrolizumab May Address Unmet Need in Advanced Urothelial Cancer

March 2nd 2023

Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.

Mesenchymal Chondrosarcoma Is a Rare Sarcoma Subtype With Challenging Diagnosis

March 2nd 2023

R. Lor Randall, MD, FACS, discusses the presentation and diagnosis of mesenchymal chondrosarcomas, the role of HEY1-NCoA2 gene fusions in the disease, and potential treatment options for this rare subgroup of patients.

SKCC’s Dr. Edith Mitchell Named Enterprise Vice President for Cancer Disparities

March 2nd 2023

Edith P. Mitchell, MD, MACP, FCCP, FRCP, Director of the Center to Eliminate Cancer Disparities and Clinical Professor of Medicine and Medical Oncology, has been named Enterprise Vice President for Cancer Disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

Groundbreaking Grant to John Theurer Cancer Center Will Establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine

March 2nd 2023

The family of Mike and Patti Hennessy made a transformational gift in their memory to establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine.

Pragmatic Approaches to Cancer Management in the Absence of Randomized Trial Data

March 2nd 2023

Phase 3 randomized trials often fail to reasonably represent the actual population of patients seen in routine community practice.

Effective Utilization of CD38+ Agents, IMiDs Spur Further Clinical Research in Relapsed/Refractory Myeloma

March 2nd 2023

Amandeep Godara, MBBS, discusses the evolving treatment landscape in both early and late relapsed multiple myeloma, updated clinical trial results with CAR T-cell therapy, and key considerations when navigating treatment selection in this disease space.

ARX788 Meets PFS End Point in HER2+ Metastatic Breast Cancer

March 1st 2023

The antibody-drug conjugate ARX788 was found to significantly improve progression-free survival compared with an active control in patients with HER2-positive locally advanced or metastatic breast cancer.

FDA Approval Sought for Niraparib Plus Abiraterone/Prednisone as First-line Treatment for BRCA+ mCRPC

March 1st 2023

A new drug application has been submitted to the FDA seeking the approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet, and prednisone, for the first-line treatment of patients with metastatic castration-resistant prostate cancer harboring BRCA mutations.

ISKS Study Links Heritable Defects With Predisposition to Sarcomas

March 1st 2023

R. Lor Randall, MD, FACS, discusses how sarcoma experts from around the world connected to collaborate on the ISKS, the importance of identifying and better understanding sarcoma subgroups, and how these findings could inform prescreening for those at risk for the disease.

New Research Shows Whole Genome Sequencing Provides Extensive Insights into Hodgkin Lymphoma

March 1st 2023

A large research project found that whole genome sequencing can provide much more information about classic Hodgkin lymphoma than exome sequencing, which reads only protein-coding genes.

FDA Approval Sought for Neoadjuvant Pembrolizumab/Chemo Plus Adjuvant Pembrolizumab in Resectable Stage II or IIIA/B NSCLC

March 1st 2023

The FDA has accepted a supplemental biologics license application for neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy, followed by adjuvant pembrolizumab monotherapy, for the treatment of patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer.

FDA Grants Orphan Drug Designation to YB-200 for Hepatocellular Carcinoma

March 1st 2023

The FDA has granted an orphan drug designation to the CEACAM1/5 antibody YB-200 for the treatment of patients with hepatocellular carcinoma.

Adding AI Analysis to Targeted Transcriptome Represents Potential Aid for Differential Diagnosis

March 1st 2023

As artificial intelligence in cancer care continues to be better understood and refined, the number of potential clinical applications is rapidly expanding.